Boston Biotech Clinical Research
  • Home
    • SCIO Path to Approval
  • Early Clinical Research
    • Strategy and TPP
    • Translational Medicine and Epigenetics
    • Biologics, Cell and Gene Therapy
    • Real World Evidence
    • Repurposing
  • Orphan Drug Solutions
    • Biomarkers and Surrogate Endpoints
    • Regulatory Affairs FDA and EMA
    • Medical Affairs and Clinical Research
    • Due Diligence
    • Trial Management & Trial Rescue
  • People
    • Senior Advisors
      • Candida Fratazzi
      • Claudio Carini
      • Federico Goodsaid
    • Our Clients
    • Our Collaborators
    • Testimonials
  • Resources
    • BBCR Voice
    • Case Studies
    • Published Studies
    • Conferences & Presentations
    • Job Opportunities
    • Contact Info
Select Page

Due Diligence

Due Diligence is critical before dedicating precious time and resources to a research project that appears to hold commercial promise.

January 4th, 2023 | Due Diligence

Increase investors’ evaluation in a competitive market. Due Diligence is typically performed by investors but can, and should, be conducted by sponsors to increase their chance of financing success, partnering, mergers, acquisitions (M&As), and product licensing. For companies developing multiple products, due Diligence can also inform and assist in deciding which products to budget for […]

Categories

  • Biomarkers & Surrogate Endpoints
  • Company News
  • Drug Development
  • Due Diligence
  • Early Clinical Development
  • Industry News
  • Medical Affairs and Clinical Research
  • Miscellaneous
  • Orphan Diseases
  • Pre-IND
  • Precision Medicine
  • Rare Disease
  • Real World Evidence
  • Regulatory
  • Regulatory Affairs
  • Strategy and TPP
  • Translation Medicine and Epigenetics
  • Trial Management
  • Trial Rescue

Recent Posts

  • Building a Stronger Path to Market Through Early Clinical Research Strategy
  • Why Early Clinical Research Strategy Is Critical to Successful Drug Development
  • Why Rare Disease Drug Development Requires a Different Clinical Strategy
  • Why do orphan drug launches require specialized strategic planning?
  • BBCR and its consultants are dedicated to advancing innovative and repurposed treatments for orphan diseases, an area where impact is high, but the path is complex.

RSS Nasdaq Globe Newswire

  • LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update August 14, 2026
  • Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement August 14, 2026
  • Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results August 14, 2026
  •  Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress August 14, 2026
PRIVACY POLICY
  • LinkedIn

©2026 Boston Biotech Clinical Research. All Rights Reserved.   |   Web Design by Nisse Designs